Our findings from a United States-wide, multicenter immunogenicity substudy conclusively demonstrate that two doses of intramuscularly administered AZD1222 induce a durable nasal anti-spike IgG response and can increase nasal IgA immunity from prior infection. This evidence concerns the gene CD79A and infection.